Marizyme (MRZM, $0.03) was a top loser over the last three months, falling -4 to $0.03 per share. A.I.dvisor analyzed 861 stocks in the Biotechnology Industry for the 3-month period ending December 12, 2024, and found that of them (3) exhibited an Uptrend while of them (6) demonstrated a Downtrend. 77 similar cases when MRZM's price dropped within three months. In out of those 77 cases, MRZM's price went down during the following month. Based on these historical data, the odds of a Downtrend continuation for MRZM are